Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson’s Disease OFF Episodes

Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson’s Disease OFF Episodes

Study to Explore the Therapeutic Benefit of Intranasal Levodopa in Parkinson’s Disease OFF Reversal (THOR 201) SEATTLE, May 31, 2018 /PRNewswire/ — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the